{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-042144","form_type":"8-K","ticker":"IVF","cik":"0001417926","company_name":"INVO Fertility, Inc.","filed_at":"2023-11-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.997238+00:00","generated_at":"2026-06-07T23:18:02.803111+00:00","sec_items":["1.01","3.02","5.03","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"INVO raises $6M equity via share exchange with Cytovia to regain Nasdaq compliance","bullets":["Issued 1.2M Series B Preferred shares to Cytovia for 163,637 NAYA shares valued at $6M.","Transaction increases stockholders' equity by $6M to meet Nasdaq $2.5M minimum requirement.","Company had Nasdaq extension through Nov 20, 2023; now expects confirmation of compliance.","Also authorized Series A Preferred for planned $5M+ private offering related to NAYA merger.","Series A and B Preferred convertible at $2.20 and $5.00 per share, with ownership caps of 9.99% and 19.99%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-042144","json":"https://secwatch.observer/filing/0001493152-23-042144.json","markdown":"https://secwatch.observer/filing/0001493152-23-042144.md","text":"https://secwatch.observer/filing/0001493152-23-042144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T23:18:02.803111+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"72a9925b89679e9e3227ad30d59cff934c36561c","claim":"INVO Fertility, Inc.: The Company filed a Certificate of Designation for Series B Convertible Preferred Stock, establishing its rights, preferences, and privileges (effective 2023-11-20).","evidence_excerpt":"On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series B Convertible Preferred Stock (the “ Series B Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series B Preferred Stock (the “ Series B Preferred ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-20"}],"fact_type":"governance_change"},{"claim_id":"de80a2ece8f15bf5fd46096ab1a881bf4d3ebd6c","claim":"INVO Fertility, Inc.: The Company filed Certificates of Designation for two new series of preferred stock: Series A Convertible Preferred Stock and Series B Convertible Preferred Stock, setting forth the rights, preferences, and privileges of each series (effective 2023-11-20).","evidence_excerpt":"On November 20, 2023, the Company filed with the Nevada Secretary of State a Certificate of Designation of Series A Convertible Preferred Stock (the “ Series A Certificate of Designation ”) which sets forth the rights, preferences, and privileges of the Series A Preferred Stock (the “ Series A Preferred ”).","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm","confidence":0.95,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-11-20"}],"fact_type":"governance_change"},{"claim_id":"f167341e1b2a0285e7179b5ae6d35cacc9f9b91e","claim":"INVO Fertility, Inc. entered into Share Exchange Agreement with Cytovia Therapeutics Holdings, Inc. (effective 2023-11-19).","evidence_excerpt":"On November 19, 2023, the Company entered into a share exchange agreement (the “ Share Exchange Agreement ”) with Cytovia Therapeutics Holdings, Inc., a Delaware corporation (“ Cytovia ”) for Cytovia’s acquisition of 1,200,000 shares of the Company’s newly designated Series B Preferred Stock in exchange for 163,637 shares of common stock of NAYA held by Cytovia valued at $6,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1417926/000149315223042144/0001493152-23-042144-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"Cytovia Therapeutics Holdings, Inc."},{"label":"Effective","value":"2023-11-19"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}